Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
61 pending office actions • 28 art units • 52 examiners • 0 of 61 (0%) have an AI response strategy ready • 65 patents granted in the last 365 days
Roche Diagnostics Operations Inc. maintains a large portfolio of 59 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 51 distinct examiners, indicating a high level of diversification in the examination process. With the examiners reviewing 59 actions, the company faces a wide array of examiner styles and preferences that could impact the speed and success of patent grants.
The portfolio's reach extends across 27 distinct art units, reflecting the broad technical scope of the company's innovations in Biotechnology & Pharmaceuticals. This count of 27 distinct art units suggests that the pending office actions cover a diverse range of sub-technologies, each with its own set of examination challenges. Managing such a distributed portfolio requires a sophisticated approach to maintain consistency across many different administrative environments.
SINES, BRIAN J is the busiest examiner for this company, currently overseeing 2 pending office actions. This is a low concentration of work, as the 2 actions handled by this examiner represent only a small portion of the total pending actions. The involvement of 51 distinct examiners across the art units underscores the complexity of the company's ongoing patent prosecution efforts.
Based on the USPTO statutory response window for each pending office action. 24 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 24 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 2 (3%) |
| §101 + other | 19 (31%) |
| §103 only | 14 (23%) |
| §102 only | 4 (7%) |
| §112 only | 4 (7%) |
| Double-patenting + other | 1 (2%) |
| Multi-statute (no §101) | 17 (28%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SINES, BRIAN J | 2 | 80.1% | +5.2% |
| BORTOLI, JONATHAN | 2 | 76.3% | +41.2% |
| WHATLEY, BENJAMIN R | 2 | 66.7% | +68.5% |
| HRANEK, KAREN AMANDA | 2 | 34.5% | +39.9% |
| COUNTS, GARY W | 2 | 58.9% | +29.5% |
| LANKFORD JR, LEON B | 2 | 70.0% | +31.6% |
| CHIU, MAY LEUNG | 2 | 44.8% | +24.4% |
| MARCSISIN, ELLEN JEAN | 2 | 34.5% | +49.3% |
| NGUYEN, NAM P | 2 | 54.8% | +48.7% |
| BUTLER, SARAI E | 1 | 88.1% | +10.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17891458 | IDENTIFICATION OF PATIENTS WITH ABNORMAL FRACTIONAL SHORTENING | MARCSISIN, ELLEN JEAN | 51d overdue |
| 18636375 | METHODS AND SYSTEMS OF SAMPLE QUALITY VERIFICATION | SANGHERA, STEVEN G.S. | 38d overdue |
| 18352183 | PROGNOSTIC VALUE OF BIOMARKERS IN PATIENTS WITH NON-SMALL CELL LUNG CANCER HAVING STABLE DISEASE | SINES, BRIAN J | 30d overdue |
| 18556849 | INFORMATION PROCESSING DEVICE FOR PROVIDING REFERENCE INFORMATION RELATING TO DIAGNOSIS OF THYROID DISEASE | HRANEK, KAREN AMANDA | 25d overdue |
| 17162140 | Use of Biomarkers in the Assessment of the Early Transition from Arterial Hypertension to Heart Failure | MARCSISIN, ELLEN JEAN | 19d overdue |
| 18561621 | sFRP4 AS BLOOD BIOMARKER FOR THE NON-INVASIVE DIAGNOSIS OF ADENOMYOSIS | COUNTS, GARY W | 8d overdue |
| 17916251 | A METHOD OF ASSESSING A FEMALE'S RISK OF HAVING PCOS AS WELL AS PRODUCTS AND USES RELATING THERETO | VOLKOV, ALEXANDER ALEXANDROVIC | 4d overdue |
| 17907039 | CORONA NUCLEOCAPSID ANTIGEN FOR USE IN ANTIBODY-IMMUNOASSAYS | JOHANSEN, PETER N. | 8d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17891458 | IDENTIFICATION OF PATIENTS WITH ABNORMAL FRACTIONAL SHORTENING | MARCSISIN, ELLEN JEAN | 51d overdue |
| 18556849 | INFORMATION PROCESSING DEVICE FOR PROVIDING REFERENCE INFORMATION RELATING TO DIAGNOSIS OF THYROID DISEASE | HRANEK, KAREN AMANDA | 25d overdue |
| 17162140 | Use of Biomarkers in the Assessment of the Early Transition from Arterial Hypertension to Heart Failure | MARCSISIN, ELLEN JEAN | 19d overdue |
| 18561621 | sFRP4 AS BLOOD BIOMARKER FOR THE NON-INVASIVE DIAGNOSIS OF ADENOMYOSIS | COUNTS, GARY W | 8d overdue |
| 15892829 | ALKALINE PRETREATMENT OF PARVOVIRUSES FOR IMMUNOASSAYS | NGUYEN, NAM P | 26d |
| 17772959 | SEPSIS MANAGEMENT | COUNTS, GARY W | 29d |
| 17838568 | PARTICLE-BASED IMMUNOASSAY USING A PEGYLATED ANALYTE-SPECIFIC BINDING AGENT | NGUYEN, NAM P | 34d |
| 17814332 | SAMPLE INPUT INTERFACE | CHIU, MAY LEUNG | 54d |
| Art Unit | Apps |
|---|---|
| 1678 | 5 |
| 1797 | 5 |
| 1677 | 4 |
| 3684 | 3 |
| 1796 | 3 |
| 2881 | 2 |
| 3651 | 2 |
| 1657 | 2 |
| 1758 | 2 |
| 1675 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19288563 | METHOD FOR DETECTING AND REPORTING AN OPERATION ERROR IN AN IN-VITRO DIAGNOSTIC SYSTEM AND AN IN-VITRO DIAGNOSTIC SYSTEM | BUTLER, SARAI E | — | §103§112Other | Non-Final OA | — | Pending | Aug 01, 2025 |
| 19004068 | SAFE POINT PATTERN | RODRIGUEZ, JOSEPH C | 3662 | §102§103§112 | Non-Final OA | — | Pending | Dec 27, 2024 |
| 19004137 | DISTRIBUTION SYSTEM AND METHOD FOR DISTRIBUTING A PLURALITY OF CARRIERS | TIGHE, BRENDAN P | — | §102 | Non-Final OA | — | Pending | Dec 27, 2024 |
| 18935834 | METHOD AND LABORATORY SYSTEM FOR DETERMINING AT LEAST ONE CONTAINER INFORMATION ABOUT A LABORATORY SAMPLE CONTAINER | SALEH, ZAID MUHAMMAD | — | §103 | Non-Final OA | — | Pending | Nov 04, 2024 |
| 18810797 | METHOD FOR IMPROVING CROSS-FLOW FILTRATION AND CROSS-FLOW FILTRATION SYSTEM | PATEL, PRANAV N | — | §103 | Non-Final OA | — | Pending | Aug 21, 2024 |
| 18719252 | METHOD FOR CHARACTERIZATION OF A MASS SPECTROMETRY INSTRUMENT COMPRISING AT LEAST ONE MASS ANALYZING CELL | WANG, JING | 2881 | §101§103§112 | Non-Final OA | — | Pending | Jun 12, 2024 |
| 18711999 | AUTOMATIC ANALYZER | SINES, BRIAN J | — | §102§103 | Non-Final OA | — | Pending | May 21, 2024 |
| 18669957 | NOVEL BIOTIN-SPECIFIC MONOCLONAL ANTIBODY AND USE THEREOF | HAQ, SHAFIQUL | 1600 | §103§112Other | Non-Final OA | — | Pending | May 21, 2024 |
| 18668368 | METHOD AND SYSTEM FOR OPERATING A LABORATORY AUTOMATION SYSTEM | BORTOLI, JONATHAN | — | §101 | Non-Final OA | — | Pending | May 20, 2024 |
| 18667208 | OPTICAL SYSTEM FOR FOURIER PTYCHOGRAPHY | HUANG, WEN | 2872 | §103 | Final Rejection | — | Pending | May 17, 2024 |
| 18649151 | TRANSPORT DEVICE AND LABORATORY SAMPLE DISTRIBUTION SYSTEM | JORGENSEN, ABBY A | 3651 | §103 | Non-Final OA | 3d overdue | Pending | Apr 29, 2024 |
| 18645358 | ON-BOARD CONJUGATION | NGUYEN, BAO THUY L | — | §102§103 | Non-Final OA | — | Pending | Apr 24, 2024 |
| 18642895 | ADJUSTABLE ADAPTER AND LABORATORY SYSTEM | WHATLEY, BENJAMIN R | — | §102§103§112 | Non-Final OA | — | Pending | Apr 23, 2024 |
| 18636375 | METHODS AND SYSTEMS OF SAMPLE QUALITY VERIFICATION | SANGHERA, STEVEN G.S. | 3684 | §101§103§112 | Non-Final OA | 38d overdue | Pending | Apr 16, 2024 |
| 18620273 | LIGHT SOURCE FOR GENERATING ILLUMINATION LIGHT | DOWNING, SAVANNAH STARR | 2884 | §103 | Final Rejection | 39d | Pending | Mar 28, 2024 |
| 18696634 | FEDERATED LEARNING OF MEDICAL VALIDATION MODEL | HRANEK, KAREN AMANDA | 3684 | §103 | Non-Final OA | — | Pending | Mar 28, 2024 |
| 18696730 | MR-PROADM MARKER PANELS FOR EARLY DETECTION OF SEPSIS | LEE, JAE W | 1759 | §101§103§112 | Non-Final OA | — | Pending | Mar 28, 2024 |
| 18692099 | CENTERING HOLDER FOR CENTERING ONE SAMPLE TUBE | WRIGHT, PATRICIA KATHRYN | — | §112 | Non-Final OA | — | Pending | Mar 14, 2024 |
| 18587217 | COMPUTER-IMPLEMENTED METHOD | WAQAS, SAAD A | 2468 | §102 | Final Rejection | 19d overdue | Pending | Feb 26, 2024 |
| 18433619 | CHIMERIC IGG-FC-BINDING LIGAND POLYPEPTIDE AND USES THEREOF FOR IGG AFFINITY PURIFICATION | SZPERKA, MICHAEL EDWARD | — | §103§112 | Non-Final OA | — | Pending | Feb 06, 2024 |
| 18579561 | TRANSFER DEVICE FOR TRANSFERRING SAMPLE CONTAINERS IN A SAMPLE HANDLING SYSTEM | WHATLEY, BENJAMIN R | — | §112 | Non-Final OA | — | Pending | Jan 16, 2024 |
| 18578369 | AUTOMATIC ANALYZER AND GUIDANCE METHOD IN AUTOMATIC ANALYZER | TURK, NEIL N | 1798 | §112 | Non-Final OA | — | Pending | Jan 11, 2024 |
| 18541476 | METHOD FOR IMMUNOSENSING ON A LIPID LAYER | DUNN, MCKENZIE A | — | §102§103DP | Non-Final OA | — | Pending | Dec 15, 2023 |
| 18541624 | UNIVERSAL CALIBRATION FOR QUANTITATIVE MASS SPECTROMETRY | ALABI, OYELEYE A | — | §101§102§103§112 | Non-Final OA | — | Pending | Dec 15, 2023 |
| 18566548 | AN ANALYZER SYSTEM | LI, LARRY | 2881 | §103 | Final Rejection | — | Pending | Dec 01, 2023 |
| 18561621 | sFRP4 AS BLOOD BIOMARKER FOR THE NON-INVASIVE DIAGNOSIS OF ADENOMYOSIS | COUNTS, GARY W | 1678 | §101§102§103§112 | Non-Final OA | 8d overdue | Pending | Nov 16, 2023 |
| 18558133 | IL6 MARKER PANELS FOR EARLY DETECTION OF SEPSIS | LANKFORD JR, LEON B | 1657 | §103 | Non-Final OA | — | Pending | Oct 30, 2023 |
| 18558150 | ESM1 MARKER PANELS FOR EARLY DETECTION OF SEPSIS | LANKFORD JR, LEON B | 1657 | §103 | Non-Final OA | — | Pending | Oct 30, 2023 |
| 18556849 | INFORMATION PROCESSING DEVICE FOR PROVIDING REFERENCE INFORMATION RELATING TO DIAGNOSIS OF THYROID DISEASE | HRANEK, KAREN AMANDA | 3684 | §101§103 | Final Rejection | 25d overdue | Pending | Oct 23, 2023 |
| 18353485 | SAMPLE VESSEL CLOSURE METHOD, MOVABLE CAP GRIPPER AND SAMPLE VESSEL CLOSURE SYSTEM FOR AUTOMATICALLY CLOSING AN OPEN END OF A SAMPLE VESSEL WITH A CLOSURE CAP | BORTOLI, JONATHAN | 1797 | §102 | Non-Final OA | — | Pending | Jul 17, 2023 |
| 18352183 | PROGNOSTIC VALUE OF BIOMARKERS IN PATIENTS WITH NON-SMALL CELL LUNG CANCER HAVING STABLE DISEASE | SINES, BRIAN J | 1796 | §101§102§103§112 | Final Rejection | 30d overdue | Pending | Jul 13, 2023 |
| 18339760 | AUTOMATED CLINICAL DIAGNOSTIC SYSTEM AND METHOD | WALLENHORST, MAUREEN | 1797 | §102§103§112 | Non-Final OA | — | Pending | Jun 22, 2023 |
| 18337018 | LC-MS METHOD FOR DETECTING AND QUANTIFYING 11-OXYGENATED STEROIDS | SODERQUIST, ARLEN | 1797 | §102§103§112 | Final Rejection | 21d | Pending | Jun 18, 2023 |
| 18333347 | INTERFERENCE MONITORING FOR PROVIDING A VERIFIED ANALYTE MEASUREMENT | HYUN, PAUL SANG HWA | 1796 | §101§102§103§112 | Final Rejection | 33d | Pending | Jun 12, 2023 |
| 18325328 | SAMPLE CONTAINER HOLDING AND/OR TRANSPORTING DEVICE | CHIU, MAY LEUNG | 1797 | §102§112 | Non-Final OA | — | Pending | May 30, 2023 |
| 18309985 | TIMP1 AS A MARKER FOR CHOLANGIOCARCINOMA | DENT, ALANA HARRIS | 1643 | §102 | Final Rejection | 20d | Pending | May 01, 2023 |
| 18299750 | GRIPPING APPARATUS FOR GRIPPING SAMPLE CONTAINER | LEEDS, DANIEL JEREMY | 3731 | §102§103 | Final Rejection | — | Pending | Apr 13, 2023 |
| 18028235 | CIRCULATING TOTAL-NT-PROBNP (GLYCOSYLATED AND UNGLYCOSYLATED NT-PROBNP) AND ITS RATIO WITH NT-PROBNP (UNGLYCOSYLATED NT-PROBNP) IN THE ASSESSMENT OF ATRIAL FIBRILLATION | FRITCHMAN, REBECCA M | 1758 | §101§103 | Final Rejection | — | Pending | Mar 24, 2023 |
| 18178595 | INTELLIGENT USER GUIDANCE FOR LABORATORY ISSUE RESOLUTION | ANDERSON, FOLASHADE | 3623 | §101 | Final Rejection | 36d | Pending | Mar 06, 2023 |
| 18021085 | IGFBP7 FOR THE ASSESSMENT OF SILENT BRAIN INFARCTS AND COGNITIVE DECLINE | WEIDNER, ADAM M | 1675 | §101§103§112 | Non-Final OA | — | Pending | Feb 13, 2023 |
| 18017073 | GDF-15 FOR PREDICTING THE DISEASE SEVERITY OF A PATIENT WITH COVID-19 | ZOU, NIANXIANG | 1671 | §101§103 | Final Rejection | 61d | Pending | Jan 19, 2023 |
| 18096477 | LC COLUMN HANDLING USING WEIGHTED COUNTERS | LEBRON, BENJAMIN L | 1773 | §101§102§103§112 | Final Rejection | — | Pending | Jan 12, 2023 |
| 17990903 | REAGENT FOR MASS SPECTROMETRY | ADAMS, MICHELLE | 1797 | §102§112 | Non-Final OA | — | Pending | Nov 21, 2022 |
| 17916251 | A METHOD OF ASSESSING A FEMALE'S RISK OF HAVING PCOS AS WELL AS PRODUCTS AND USES RELATING THERETO | VOLKOV, ALEXANDER ALEXANDROVIC | 1677 | §101§103§112 | Final Rejection | 4d overdue | Pending | Sep 30, 2022 |
| 17907039 | CORONA NUCLEOCAPSID ANTIGEN FOR USE IN ANTIBODY-IMMUNOASSAYS | JOHANSEN, PETER N. | 1644 | §103§112 | Final Rejection | 8d | Pending | Sep 22, 2022 |
| 17931993 | CARRY-OVER MONITORING | HILL, GRACELYN MARKHAM | 1685 | §101§103 | Non-Final OA | 13d | Pending | Sep 14, 2022 |
| 17893574 | CLINICAL DECISION SUPPORT ON CLINICAL ANALYZER | HIGGS, STELLA EUN | 3681 | §103 | Final Rejection | — | Pending | Aug 23, 2022 |
| 17891458 | IDENTIFICATION OF PATIENTS WITH ABNORMAL FRACTIONAL SHORTENING | MARCSISIN, ELLEN JEAN | 1677 | §101§103§112 | Final Rejection | 51d overdue | Pending | Aug 19, 2022 |
| 17814332 | SAMPLE INPUT INTERFACE | CHIU, MAY LEUNG | 1758 | §102§103§112 | Final Rejection | 54d | Pending | Jul 22, 2022 |
| 17838568 | PARTICLE-BASED IMMUNOASSAY USING A PEGYLATED ANALYTE-SPECIFIC BINDING AGENT | NGUYEN, NAM P | 1678 | §103 | Final Rejection | 34d | Pending | Jun 13, 2022 |
| 17664230 | METHOD AND DISTRIBUTION SYSTEM TO MOVE CARRIERS ON A TRANSPORT PLANE | CUMBESS, YOLANDA RENEE | 3651 | §102§103§112 | Final Rejection | 36d | Pending | May 20, 2022 |
| 17772959 | SEPSIS MANAGEMENT | COUNTS, GARY W | 1678 | §101§103 | Non-Final OA | 29d | Pending | Apr 28, 2022 |
| 17402808 | LOCATION-BASED ACCESS CONTROL OF A MEDICAL ANALYZER | MOHAMMADI, FAHIMEH M | 2439 | §103 | Non-Final OA | — | Pending | Aug 16, 2021 |
| 17444397 | SAMPLE CONTAINER TRANSPORT SYSTEM | LE, AUSTIN Q | 1796 | §103§112 | Non-Final OA | — | Pending | Aug 04, 2021 |
| 17360121 | DETECTION OF BACTERIAL (MOLLICUTIES) CONTAMINATION | BERTAGNA, ANGELA MARIE | 1681 | §101§103§112 | Final Rejection | 14d | Pending | Jun 28, 2021 |
| 17162140 | Use of Biomarkers in the Assessment of the Early Transition from Arterial Hypertension to Heart Failure | MARCSISIN, ELLEN JEAN | 1677 | §101§103§112 | Final Rejection | 19d overdue | Pending | Jan 29, 2021 |
| 17150504 | METHODS OF IDENTIFYING AN INDIVIDUAL AS HAVING OR BEING AT RISK OF DEVELOPING AN AMYLOID-POSITIVE DEMENTIA BASED ON MARKER MOLECULES AND RELATED USES | RAMADAN, OMAR | 1678 | §101§102§103§112 | Final Rejection | — | Pending | Jan 15, 2021 |
| 16825181 | MULTIVALENT MONO- OR BISPECIFIC RECOMBINANT ANTIBODIES FOR ANALYTIC PURPOSE | ESSEX, LAURA ANN | 1675 | §103 | Non-Final OA | — | Pending | Mar 20, 2020 |
| 16008281 | FKBP DOMAIN WITH TRANSGLUTAMINASE RECOGNITION SITE | DABKOWSKI, ERINNE R | 1654 | §112 | Final Rejection | 42d overdue | Pending | Jun 14, 2018 |
| 15965748 | METHODS AND SYSTEMS FOR ANALYZING TISSUE QUALITY USING MID-INFRARED SPECTROSCOPY | KIRWIN, STEFANIE JOHANNA | 1677 | §103Other | Non-Final OA | — | Pending | Apr 27, 2018 |
| 15892829 | ALKALINE PRETREATMENT OF PARVOVIRUSES FOR IMMUNOASSAYS | NGUYEN, NAM P | 1678 | §103§112 | Non-Final OA | 26d | Pending | Feb 09, 2018 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial